Drug Trial Radar · NCT05955391
TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
164
Actual
Start
Jan 18, 2023
Primary completion
Dec 29, 2024
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Shenzhen TargetRx Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Sun Yat-Sen University Cancer Center; Tongji Hospital; Sichuan Cancer Hospital and Research Institute; The First Affiliated Hospital of Zhengzhou University; West China Hospital; First Affiliated Hospital of Zhejiang University; Jilin Provincial Tumor Hospital; Hunan Cancer Hospital; Shandong Cancer Hospital and Institute; Jiangxi Provincial Cancer Hospital; First Hospital of China Medical University; The Affiliated Hospital of Qingdao University; Liaoning Cancer Hospital & Institute; Haerbin Medical University Cancer Hospital; Xinxiang Central Hospital; Xiangyang Central Hospital; Mianyang Central Hospital; Zhejiang Cancer Hospital; Henan Cancer Hospital; First Affiliated Hospital, Sun Yat-Sen University; The First Affiliated Hospital of Bengbu Medical University; Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center; Bingzhou Medical University Affiliated Hospital; Fujian Cancer Hospital; Ningbo No. 1 Hospital; First Affiliated Hospital Xi'an Jiaotong University; The Second Affiliated Hospital of AFMU; Yunnan Cancer Hospital; Capital Medical School Beijing Chest Hospital; Shijiazhuang People's Hospital; Tianjin Cancer Hospital Airport Hospital; Affiliated Cancer Hospital of Guizhou Medical University; Nanchang University First Affiliated Hospital; Jingzhou First People's Hospital; Shanghai Chest Hospital
- First posted
- Jul 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, single-arm, open-label, Phase II clinical trial which explores the safety and efficacy of TGRX-326 in patients with ALK-positive advanced NSCLC who have failed prior 2nd-generation ALK treatments due to progressive disease or intolerance.
Conditions
- Non-small Cell Lung Cancer
Interventions
TGRX-326Drug
Subjects will be treated with the investigational drug TGRX-326 at 60 mg once day in 21-day cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Every 2 cycles between Cycle 1 and Cycle 17, and every 12 weeks from Cycle 17 and onwards (every cycle is 21 days); an average of 1.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.